IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia

A method of treating a subject with an IL-7Rα positive cancer, comprising:

• administering to the subject a therapeutically effective amount of:
• (A) a monoclonal antibody that specifically binds to an extracellular domain of IL-7Rα, the monoclonal antibody comprising:
• a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
• 1 (4A10 VH) and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
• 2 (4A10 VL), or
• a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
• 3 (2B8 VH) and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
• 4 (2B8 VL);
• (B) an antigen binding fragment of the monoclonal antibody;
• or
• (C) a bispecific antibody comprising the monoclonal antibody or the antigen binding fragment;
• and
• administering to the subject a therapeutically effective amount of an additional agent, wherein the additional agent comprises a chemotherapeutic agent, an alkylating agent, an antimetabolite, a vinca alkaloid, an epipodophyllotoxin, an antibiotic, an adrenocorticosteroid, or a C—X—C chemokine receptor type 4 (CXCR4) antagonist, thereby treating the IL-7Rα positive cancer.